EVALUATION OF INTRAVITREAL RANIBIZUMAB INJECTION INFLUENCE ON TEAR FLUID IMMUNE STATUS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
- Authors: Kuznecov A.A.1,2, Tur E.V.1, Ishmakov K.S.2
-
Affiliations:
- South-Ural State Medical University
- Chelyabinsk Regional Clinical Hospital
- Issue: Vol 20, No 2 (2017)
- Pages: 159-161
- Section: Articles
- URL: https://journal-vniispk.ru/1028-7221/article/view/119599
- ID: 119599
Cite item
Full Text
Abstract
Influence of intravitreal injection of vascular endothelial growth factor A inhibitor (VEGF-A) for aged-related macular degeneration treatment on tear fluid immune status, which was evaluated by multiplex analysis with assay of BasicFGF, Eotaxin, G-CSF, GM-CSF, INF-γ, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-1β, IL-1ra, IL- 2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF- a, VEGF was studied. The study showed that given treatment result in a significant decrease in BasicFGF, Eotaxin, IL-13, TNF-α levels in tear fluid in one month.
About the authors
A. A. Kuznecov
South-Ural State Medical University; Chelyabinsk Regional Clinical Hospital
Author for correspondence.
Email: noemail@neicon.ru
Russian Federation
E. V. Tur
South-Ural State Medical University
Email: noemail@neicon.ru
Russian Federation
K. S. Ishmakov
Chelyabinsk Regional Clinical Hospital
Email: noemail@neicon.ru
Russian Federation
References
- Clemons T. E., Milton R. C., Clein R et al. Risk factors for the incidence of advanced age-related mac-ular degeneration in the Age-Related Eye disease Study (AREDS). AREDS report number 19. Ophthalmology 2005, 112,533-539.
- Resnikoff S., Pascolini D., Etya'ale D., et al. Global data on visual impairment in the year 2002. Bulletin of the World Health Organization 2004, 82 (11), 844-851.
- Khan M., Agarwal K., Loutfi M., Kamal A. Present and Possible Therapies for Age-Related Macular Degeneration. ISRN Ophthalmology 2014, article ID 608390, 7 pages.
- Кузнецов А. А., Тур Е. В., Ишмаков К. С. Оценка уровня цитокинов слезы у условно здоровых лиц в возрасте старше 50 лет. Российский иммунологический журнал 2016, 10, 3(1) (19), 294-296.
Supplementary files
